Document:

Exhibit 10.18

 

David Sinclair

Name of Consultant

 

SIRTRIS PHARMACEUTICALS, INC.

Amended and Restated 2004 Incentive
Plan

 

Restricted Stock Award Agreement

 

Sirtris Pharmaceuticals, Inc.

200 Technology Square

Cambridge, MA 02139

 

Ladies and Gentlemen:

 

The undersigned (i) acknowledges
that he has received an award (the “Award”) of restricted stock from Sirtris
Pharmaceuticals, Inc. (the “Company”) under the Amended and Restated 2004
Incentive Plan (the “Plan”), subject to the terms set forth below and in the
Plan; (ii) further acknowledges receipt of a copy of the Plan as in effect
on the date hereof; and (iii) agrees with the Company as follows:

 

1.             Effective Date.  This Agreement
shall take effect as of January 2, 2008, which is the date of grant of the
Award.

 

2.             Shares Subject to Award.  The
Award consists of 20,000 shares (the “Shares”) of common stock of the Company (“Stock”). 
The undersigned’s rights to the Shares are subject to the restrictions
described in this Agreement and the Plan (which is incorporated herein by
reference with the same effect as if set forth herein in full) in addition to
such other restrictions, if any, as may be imposed by law.

 

3.             Meaning of Certain Terms.  Except
as otherwise expressly provided, all terms used herein shall have the same
meaning as in the Plan.  The term “vest” as used herein with respect to
any Share means the lapsing of the restrictions described herein with respect
to such Share.

 

4.             Nontransferability of Shares. 
The Shares acquired by the undersigned pursuant to this Agreement shall not be
sold, transferred, pledged, assigned or otherwise encumbered or disposed of
except as provided below and in the Plan.

 

5.             Forfeiture Risk.  If the
undersigned ceases to serve as a consultant to the Company and its subsidiaries,
any then outstanding and unvested Shares acquired by the undersigned hereunder
shall be automatically and immediately forfeited.  With respect to any
Shares that are forfeited under this Section 5, the undersigned hereby (i) appoints
the Company as the attorney-in-fact of the undersigned to take such actions as
may be necessary or appropriate to effectuate a transfer of the record
ownership of any such shares that are unvested and forfeited hereunder, (ii) agrees
to deliver to the Company, as a precondition to the issuance of any certificate
or certificates with respect to unvested Shares hereunder, one or more stock
powers, endorsed in blank, with respect to such Shares, and (iii) agrees
to sign such other powers and take such other actions as the Company may
reasonably request to accomplish the transfer or forfeiture of any unvested
Shares that are forfeited hereunder.

 

6.             Retention of Certificates.  Any
certificates representing unvested Shares shall be held by the Company. 
If unvested Shares are held in book entry form, the undersigned agrees that the
Company may give stop transfer instructions to the depository to ensure
compliance with the provisions hereof.

 

 

 

7.             Vesting of Shares.  The shares
acquired hereunder shall vest in accordance with the provisions of this Section 7
and applicable provisions of the Plan, as follows: 20% of the Shares on January 1,
2010, an additional 30% of the Shares on January 1, 2011, and an
additional 50% of the Shares on January 1, 2012, provided that, the
portion of the Shares that would otherwise vest on January 1, 2012 (the “Final
Tranche”) will vest as follows, if earlier than January 1, 2012:  (a) one-half of the Final Tranche (25%
of the total number of Shares) shall vest upon completion of a Board approved
corporate partnership for a SIRT1 activator that the Board determines to be “significant”
for this purpose and (b) one-half of the Final Tranche (25% of the total
number of the Shares) shall vest upon positive clinical efficacy data for a
Sirtris NCE SIRT1 activator as demonstrated by safely meeting the primary
efficacy endpoint of a Sirtris-sponsored Phase 2a or 2b clinical trial in Type
2 diabetes, obesity or a metabolic syndrome.

 

Notwithstanding the foregoing, no shares shall vest on
any vesting date specified above unless the undersigned is then, and since the
date of grant has continuously been involved as a consultant of the Company or
its subsidiaries.

 

8.             Legends.  Any certificates
representing unvested Shares shall be held by the Company, and any such
certificate shall contain legend substantially in the following form:

 

THE TRANSFERABILITY OF THIS CERTIFICATE AND THE SHARES
OF STOCK REPRESENTED HEREBY ARE SUBJECT TO THE TERMS AND CONDITIONS (INCLUDING
FORFEITURE) OF THE AMENDED AND RESTATED 2004 INCENTIVE PLAN AND A RESTRICTED
STOCK AWARD AGREEMENT ENTERED INTO BETWEEN THE REGISTERED OWNER AND SIRTRIS
PHARMACEUTICALS, INC.  COPIES OF SUCH PLAN AND AGREEMENT ARE ON FILE IN
THE OFFICES OF SIRTRIS PHARMACEUTICALS, INC.

 

As soon as practicable following the vesting of any
such Shares the Company shall cause a certificate or certificates covering such
vested Shares to be issued and delivered to the undersigned without the first
legend set forth above referencing the Restricted Stock Award Agreement. 
If any Shares are held in book-entry form, the Company may take such steps as
it deems necessary or appropriate to record and manifest the restrictions
applicable to such Shares.

 

9.             Dividends, etc..  The undersigned
shall be entitled to (i) receive any and all dividends or other
distributions paid with respect to those Shares of which he is the record owner
on the record date for such dividend or other distribution, and (ii) vote
any Shares of which he is the record owner on the record date for such vote; provided, however, that any property
(other than cash) distributed with respect to a share of Stock (the “associated
share”) acquired hereunder, including without limitation a distribution of
Stock by reason of a stock dividend, stock split or otherwise, or a distribution
of other securities with respect to an associated share, shall be subject to
the restrictions of this Agreement in the same manner and for so long as the
associated share remains subject to such restrictions, and shall be promptly
forfeited if and when the associated share is so forfeited;  and further provided, that the
Administrator may require that any cash distribution with respect to the Shares
other than a normal cash dividend be placed in escrow or otherwise made subject
to such restrictions as the Administrator deems appropriate to carry out the
intent of the Plan.  References in this Agreement to the Shares
shall  refer, mutatis mutandis,
to any such restricted amounts.

 

10.           Sale of Vested Shares.  The
undersigned understands that he will be free to sell any Share once it has
vested, subject to (i) satisfaction of any applicable tax withholding
requirements with respect to the vesting or transfer of such Share; (ii) the
completion of any administrative steps (for example, but without limitation,
the transfer of certificates) that the Company may reasonably impose; and (iii) applicable
requirements of federal and state securities laws.

 

2

 

11.           Certain Tax Matters.  The
undersigned expressly acknowledges the following:

 

a.             The
undersigned has been advised to confer promptly with a professional tax advisor
to consider whether the undersigned should make a so-called “83(b) election”
with respect to the Shares.  Any such election, to be effective, must be
made in accordance with applicable regulations and within thirty (30) days
following the date of this Award.  The Company has made no recommendation
to the undersigned with respect to the advisability of making such an election.

 

b.             The
award or vesting of the Shares acquired hereunder, and the payment of dividends
with respect to such Shares, may give rise to “wages” subject to
withholding.  The undersigned expressly acknowledges and agrees that his
rights hereunder are subject to his promptly paying to the Company in cash (or
by such other means as may be acceptable to the Company in its discretion,
including, if the Administrator so determines, by the delivery of previously
acquired Stock or shares of Stock acquired hereunder or by the withholding of
amounts from any payment hereunder) all taxes required to be withheld in
connection with such award, vesting or payment.

 

	
   

  	
  Very truly yours,

  
	
   

  	
   

  
	
   

  	
  /s/ David Sinclair

  
	
   

  	
  (Signature of Employee)

  

 

Dated: January 2, 2008

 

The foregoing Restricted
Stock

Award Agreement is hereby
accepted:

 

SIRTRIS
PHARMACEUTICALS, INC.

 

 

	
  By

  	
  /s/ Christoph Westphal

  	
   

  

 

3Exhibit 10.19

 

SIRTRIS PHARMACEUTICALS, INC.

 

April 15, 2005

 

David Sinclair

Harvard Medical School

Department of Pathology

NRB, 9th Floor

77 Avenue Louis Pasteur

Boston, MA 02115

 

Dear David:

 

        Thank
you for agreeing to become a consultant to Sirtris Pharmaceuticals, Inc.
(the “Company”). This letter is to confirm our understanding with respect to
the services the Company will ask of you, the compensation you will receive in
return and certain related matters. We have agreed as follows.

 

        1.    Services.    You
agree to serve as a consultant to the Company under the terms of this
Agreement. You will report directly to the Chief Executive Officer of the
Company and perform such tasks as the Chief Executive Officer may request (the “Services”).
It is anticipated that the Services will include presenting data to SAB and
BOD, fundraising, grant writing, assisting the SVP Research and Director of
Biology in the design of experiments and clinical trials, evaluation and
recruitment of employees, business development, strategic planning, providing
specific advice and intellectual property unless it is confidential or
conflicts with the policy of Harvard Medical School regarding information
dissemination. You agree to make yourself available to render the Services on
an on-call basis, as requested by the Company at such times and locations as
may be mutually agreed subject to the other terms of this Agreement. You will
use commercially reasonable efforts in rendering services to and promoting the
best interests of the Company. It is understood that pursuant to your
commitments to Harvard, your activities with the Company cannot exceed 20% of
your total working time.

 

        2.    Approvals.    You
represent that you have received the requisite approvals that will allow you to
perform the Services contemplated by this Agreement.

 

        3.    Term.    The
term of this Agreement shall commence as of March 1, 2005 and shall
continue until February 28, 2006. The term of this Agreement may be
extended by mutual agreement between you and the Company. You may terminate
this Agreement at any time, with or without cause, on 60 days prior notice
to the Company. The Company may terminate this Agreement at any time, with or
without cause, upon 60 days written notice to the Consultant.

 

        4.    Expenses.    We
will reimburse you for reasonable and necessary expenses which are incurred in
connection with your performance of the Services hereunder and with respect to
which you promptly provide to us a detailed expense account and receipts,
provided that any expenses (other than travel expenses incurred in connection
with attendance at a meeting of the Scientific Advisory Board) in excess of
$500 per month have been approved by the Company in advance and in writing.

 

        5.    Compensation.    As
compensation for you providing the Services to the Company, you will be paid
one hundred and fifty thousand dollars ($150,000) per annum, payable in twelve
equal monthly installments in arrears by the last day of each month.

 

        6.    Confidentiality, Etc.    As
a condition of your engagement as a consultant by the Company, you will execute
the Company’s Consultant Non-Solicitation, Non-Disclosure and Proprietary
Information Assignment Agreement in the form attached to this Agreement as Exhibit A (the “Non-Disclosure
Agreement”).

 

 

        7.    Independent Contractor.    It
is agreed that you will perform your Services to the Company as an independent
contractor and that nothing in this agreement shall in any way be construed to
give rise to an employment relationship between you and the Company. You will
not be eligible for any employee benefits.

 

        8.    Representations; Consent.    You
represent and warrant that you have no commitments or obligations inconsistent
with this Agreement or the Non-Disclosure Agreement or that would in any way
restrict your activities as a consultant to the Company. You consent to being
named as a consultant to the Company in press releases, offering documents,
reports or other documents in printed or electronic form, and any documents
filed with the Securities and Exchange Commission.

 

        9.    Miscellaneous.    This
agreement constitutes the entire understanding of the parties with respect to
the subject matter hereof and supersedes all prior or current understandings
and agreements, whether written or oral, with respect to such subject matter.
The invalidity or unenforceability of any provision hereof shall not affect the
validity and enforceability of any other term or provision hereof. You may not
assign your rights or delegate your responsibilities under this agreement
without our prior written consent. The provision of the Non-Disclosure
Agreement. This agreement shall be governed by and construed in accordance with
the laws (other than the conflict of laws principles) of the Commonwealth of
Massachusetts. The parties agree that any disputes between the parties shall be
resolved pursuant to final and binding arbitration before a single arbitrator
selected from and administered by the American Arbitration Association in
accordance with its then existing arbitration rules or procedures
regarding business disputes.

 

        Again,
thank you for agreeing to become a consultant to the Company. We look forward
to working with you and believe that your service will be significant to the
long-term success and viability of the Company. If this letter accurately sets
forth our agreement, please so indicate by signing below on both copies of this
letter and returning both to us. We will forward to you a fully executed
agreement for your files.

 

	
  Very truly yours,

  	
   

  
	
   

  	
   

  	
   

  
	
  SIRTRIS
  PHARMACEUTICALS, INC.

  	
   

  
	
   

  	
   

  	
   

  
	
  By:

  	
   /s/  CHRISTOPH WESTPHAL  

  	
   

  
	
  Name:

  	
  Christoph Westphal

  	
   

  
	
  Title:

  	
  President and Chief
  Executive Officer

  	
   

  
	
  Date:

  	
  4/15/05

  	
   

  
	
   

  	
   

  	
   

  
	
  Agreed and Accepted

  	
   

  
	
   

  	
   

  	
   

  
	
   /s/  DAVID SINCLAIR  

  	
   

  
	
  Name:

  	
  David Sinclair

  	
   

  
	
  Date:

  	
  4/15/05

  	
   

  

 

 

Sirtris
Pharmaceuticals, Inc.

790 Memorial Drive, Suite 104

Cambridge, MA 02139

 

        March 5,
2006

 

 

David A. Sinclair

8 Preston Road

West Roxbury, MA 02132

 

Re:  Relationship with
Sirtris Pharmaceuticals, Inc.

 

Dear David:

 

        This
amends the consulting agreement between you and Sirtris dated April 15,
2005. The Term of the agreement is hereby amended to extend until Feb 28, 2007.

 

        This
amendment will be effective as of March 1, 2006. Except as described in
this amendment, the letter agreement will continue in accordance with its
original terms.

 

        If
this is your understanding, please sign this letter in duplicate in the space
provided below and return an executed copy to me. The other copy if for your
records.

 

	
   

  	
  Very truly yours,

  
	
   

  	
   

  
	
   

  	
   /s/  CHRISTOPH WESTPHAL 

  
	
   

  	
  Christoph Westphal,
  M.D., Ph.D. 

  
	
   

  	
  Vice Chair and CEO

  
	
   

  	
   

  

 

Acknowledged
and Agreed

 

	
   /s/  DAVID A. SINCLAIR  

  	
   

  
	
  David A. Sinclair

  	
   

  
	
   

  	
   

  

 

 

 

 

February 26, 2007

 

David A. Sinclair

8 Preston Road

West Roxbury, MA 02132

 

Re:

 

Relationship
with Sirtris Pharmaceuticals, Inc.

 

Dear David:

 

        This
letter amends the consulting agreement between you and Sirtris Pharmaceuticals, Inc.
dated April 5, 2005 and the letter agreement amendment to that agreement
dated March 5, 2006 as follows:

 

·  The term of the agreement is hereby
amended to extend to February 29, 2008

 

        Except
for the change in duration of the agreement all other terms of the consulting
agreement and the amendment thereto remain unchanged.

 

	
  Sincerely,

  	
   

  
	
   

  	
   

  
	
   /s/ CHRISTOPH WESTPHAL   

  	
   

  
	
  Christoph Westphal

  	
   

  
	
  Vice Chairman and Chief
  Executive Officer

  	
   

  
	
   

  	
   

  
	
  Acknowledged and
  agreed:

  	
   

  
	
   

  	
   

  
	
   /s/ DAVID A. SINCLAIR  

  	
   

  
	
  David A. Sinclair

  	
   

  
	
   

  	
   

  

 

Sirtris
Pharmaceuticals, Inc.

790 Memorial Drive, Suite 104

Cambridge, MA 02139

 

 

 

 

 

February 8, 2008

 

 

David A. Sinclair

43 Newbrook Circle

Chestnut Hill, MA 02467

 

 

Re:
Relationship with Sirtris Pharmaceuticals, Inc.

 

 

Dear David:

 

This letter amends the
consulting agreement between you and Sirtris Pharmaceuticals, Inc. dated April 5,
2005 and the letter agreement amendments to that agreement date March 5,
2006 and February 26, 2007 as follows:

 

•       The term of the agreement is hereby
amended to extend to February 28, 2009

 

Except for the change in
duration of the agreement, all other terms of the consulting agreement and the
amendments thereto remain unchanged.

 

 

Sincerely,

 

	
   /s/ Christoph Westphal

  	
   

  
	
  Christoph Westphal

  	
   

  
	
  Vice Chairman and Chief
  Executive Officer

  	
   

  
	
   

  	
   

  
	
   

  	
   

  
	
  Acknowledged and agreed:

  	
   

  
	
   

  	
   

  
	
   /s/ David A. Sinclair

  	
   

  
	
  David A. Sinclair

  	
   

  
	
   

  	
   

  

 

 

Sirtris
Pharmaceuticals, Inc.

200 Technology Square

Cambridge, MA 02139

617-252-6920

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00139-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00139-of-00352.parquet"}]]